Chemical Engineering @ChemengFiles.Com

Nerviano Medical Sciences (NMS) has obtained approval from the Food and Drug Administration (FDA) for first clinical trials of a new antitumor agent. The drug blocks Cdc7, a protein that is responsible for the uncontrolled proliferation of cancer cells. Preclinical data recently published in Nature Chemical Biology, show that the inhibition of Cdc7 induces cell death and blocked tumor growth of several types of cancer in experimental animal models.

FDA will conduct Phase I clinical trials in cancer patients. "The announcement that the FDA has approved clinical trial of our Cdc7 inhibitor - doctorFrancesco explained Colotte, vice president of NMS Oncology - first is a recognition of the quality and innovation of the Italian research in the field of oncology. The discovery of This new drug is the result solely of the efforts of our researchers in the NMS R & D Site in Nerviano, thanks to their passion and be the first in the world to explore this new antitumoral mechanism.